Bill Haddad, Author at Spark Newswire

8 minute read

September 1, 12:08 PM

Response to further allegations issues by Hindenburg on August 31, 2023: Conduct of the Investigations We stated the following within our press release dated August 30, 2023: “At the direction of the

TIO

1 minute read

Carmell Therapeutics Announces Merger With Axolotl Biologix; Axolotl Shareholders To Receive $65M In Initial Equity Value Plus Up To $75M In Milestone Equity Payments

By Bill Haddad

July 27, 7:06 AM

Transaction Details: Per the terms of the Merger Agreement, Axolotl's shareholders will receive $65 million in Initial Equity Value (structured as $8 million in cash and $57

CTCX

1 minute read

ChromaDex Highlights Publication On Abstracts In Association for Research in Vision and Ophthalmology Journal

By Bill Haddad

July 18, 8:33 AM

ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+), announced promising findings from two independent clinical study abstracts originally presented this past April at

CDXC

2 minute read

Lightwave Logic Announces Issuance Of U.S. Patent For Innovative Process To More Efficiently Pole Electro-Optic Polymers

By Bill Haddad

June 22, 8:32 AM

Company Further Strengthens IP Portfolio with Patent Issuance to More Efficiently Pole Advanced Structural Material Designs For Commercial Foundry Fabrication

LWLG

2 minute read

Cidara Therapeutics Receives FDA Fast Track Designation For CD388, A Novel Drug-Fc Conjugate Targeting Influenza A And B

By Bill Haddad

June 22, 8:01 AM

Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to save lives and improve the standard of care for patients facing serious diseases, today announced that the U.S.

CDTX

1 minute read

Roivant Reports Chronic Period Data For RVT-3101 From TUSCANY-2 Phase 2b Study In Ulcerative Colitis; Phase 3 Once-Monthly Subcutaneous Dose Resulted In Improved Clinical Remission

By Bill Haddad

June 22, 7:35 AM

This is the first-ever long-duration data reported for an anti-TL1A antibody At the expected Phase 3 once-monthly subcutaneous dose in the overall population, RVT-3101 treatment resulted in improved Clinical

ROIV

2 minute read

Amarin Announces Vascepa Approved To Reduce Cardiovascular Risk In Kingdom Of Saudi Arabia

By Bill Haddad

June 21, 9:05 AM

-- VASCEPA® Approved in KSA To Reduce the Risk of Cardiovascular (CV) Events as an Adjunct to Statin Therapy in Adult Patients with Elevated Triglyceride (TG) Levels (≥150 mg/dL) and Other High-Risk Characteristics as Studied in REDUCE-IT--

AMRN

1 minute read

Here’s Why Farfetch Shares Are Rallying After Hours

By Bill Haddad

May 18, 5:11 PM

Farfetch (NYSE: FTCH) shares are trading higher after the company reported better-than-expected Q1 results, with EPS and sales beating consensus estimates.

FTCH

1 minute read

‘Japan to subsidize half of costs for lithium and key mineral projects’ -Nikkei

By Bill Haddad

April 22, 3:53 PM

https://asia.nikkei.com/Economy/Japan-to-subsidize-half-of-costs-for-lithium-and-key-mineral-projects#:~:text=Japan%20to%20subsidize%20half%20of%20costs%20for%20lithium%20and%20key%20mineral%20projects,-Push%20to%20reduc https://asia.nikkei.com/Economy/Japan-to-subsidize-half-of-costs-for-lithium-and-key-mineral-projects#:~:text=Japan%20to%20subsidize%20half%20of%20costs%20for%20lithium%20and%20key%20mineral%20projects,-Push%20to%20reduce&text=TOKYO%20%2D%2D%20The%20Ministry%20of,Japanese%20companies%2C%20Nikkei%20has%20learned.

EWJ

1 minute read

ImmunoPrecise’s Subsidiary Talem Enters Exclusive Research Collaboration And License Option Agreement With Astellas

By Bill Haddad

March 30, 8:05 AM

ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) ("ImmunoPrecise" or "IPA" or the "Company") an AI-driven biotherapeutic research and technology company today announced a research collaboration

IPA